Sign in
PFE-PFIZER INC

Pfizer Remains an Attractive Investment with Strong Dividend Yield and Promising Oncology Growth Despite Recent Stock Declines

Thursday

05 December, 2024

Despite recent stock declines, Pfizer's commitment to a 6.7% dividend yield and a thriving oncology division signal resilience and potential growth. Can a strategic pivot in cancer therapies and an ambitious acquisition reshape investor confidence in the pharmaceutical giant?

article image for PFE

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
62
Key Takeaways
  • Pfizer offers a high dividend yield of around 6.7% with a strong history of annual increases.
  • The oncology sector is experiencing significant growth, with a 31% increase in sales from key therapies.
  • Analysts forecast a solid annual earnings growth of 10-11% in the coming years.
  • The recent acquisition of Seagen for $43 billion is expected to boost Pfizer's growth potential.
  • With a low forward P/E ratio of approximately 8.8, Pfizer is seen as undervalued in the market.
More on PFIZER INC
Read more insights on PFIZER INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.